EP4466013A4 - Chimäre polypeptide - Google Patents

Chimäre polypeptide

Info

Publication number
EP4466013A4
EP4466013A4 EP23742625.9A EP23742625A EP4466013A4 EP 4466013 A4 EP4466013 A4 EP 4466013A4 EP 23742625 A EP23742625 A EP 23742625A EP 4466013 A4 EP4466013 A4 EP 4466013A4
Authority
EP
European Patent Office
Prior art keywords
chimary
polypeptides
chimary polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23742625.9A
Other languages
English (en)
French (fr)
Other versions
EP4466013A1 (de
Inventor
Eric Charles Reynolds
Nada Slakeski
Neil O'brien-Simpson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denteric Pty Ltd
Original Assignee
Denteric Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2022900102A external-priority patent/AU2022900102A0/en
Application filed by Denteric Pty Ltd filed Critical Denteric Pty Ltd
Publication of EP4466013A1 publication Critical patent/EP4466013A1/de
Publication of EP4466013A4 publication Critical patent/EP4466013A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22037—Gingipain R (3.4.22.37)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22047—Gingipain K (3.4.22.47)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP23742625.9A 2022-01-20 2023-01-20 Chimäre polypeptide Pending EP4466013A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2022900102A AU2022900102A0 (en) 2022-01-20 Chimeric polypeptides
PCT/AU2023/050031 WO2023137522A1 (en) 2022-01-20 2023-01-20 Chimeric polypeptides

Publications (2)

Publication Number Publication Date
EP4466013A1 EP4466013A1 (de) 2024-11-27
EP4466013A4 true EP4466013A4 (de) 2026-02-11

Family

ID=87347558

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23742625.9A Pending EP4466013A4 (de) 2022-01-20 2023-01-20 Chimäre polypeptide

Country Status (7)

Country Link
EP (1) EP4466013A4 (de)
JP (1) JP2025504871A (de)
KR (1) KR20240149406A (de)
CN (1) CN118946367A (de)
AU (1) AU2023208227A1 (de)
CA (1) CA3248848A1 (de)
WO (1) WO2023137522A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121909042A (zh) * 2023-07-26 2026-04-21 卡德摩斯动物健康有限公司 嵌合蛋白疫苗
AU2024301059A1 (en) * 2023-07-26 2026-01-08 Denteric Pty Ltd Rna vaccines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ485999A0 (en) * 1999-12-24 2000-02-03 Csl Limited P. gingivalis antigenic composition
CA2735171C (en) * 2008-08-29 2023-10-03 Oral Health Australia Pty Ltd Prevention, treatment and diagnosis of p.gingivalis infection
WO2014183168A1 (en) * 2013-05-14 2014-11-20 Oral Health Australia Pty Ltd Inhibitory propeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
JP2025504871A (ja) 2025-02-19
CA3248848A1 (en) 2023-07-27
KR20240149406A (ko) 2024-10-14
WO2023137522A1 (en) 2023-07-27
EP4466013A1 (de) 2024-11-27
CN118946367A (zh) 2024-11-12
AU2023208227A1 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
EP4225364A4 (de) Präfusionsstabilisierte hmpv-f-proteine
EP4125379C0 (de) Antimykotische polypeptide
EP4089111A4 (de) Neuer polypeptidkomplex
KR20240099224A9 (ko) 항원 결합 폴리펩티드, 항원 결합 폴리펩티드 복합체 및 이의 사용 방법
EP4573551A4 (de) Vorhersage der proteinstruktur
EP4257597A4 (de) Lactammodifizierte polypeptidverbindungen
IL292097A (en) Recombinant polypeptides for regulatable cellular localization
EP4363454A4 (de) Polypeptide zum targeting von cd70-positiven krebsen
EP4460512A4 (de) Interleukin-2-polypeptide
EP4466012A4 (de) Chimäre polypeptide
EP4466013A4 (de) Chimäre polypeptide
EP4466011A4 (de) Chimäre polypeptide
EP3768720A4 (de) Neuartiges anti-lag-3-antikörper-polypeptid
EP3802565A4 (de) Polypeptide
DK4034555T3 (da) Dap10/dap12-fusionspolypeptider
EP4081241A4 (de) Regenerative polypeptide und verwendungen dafür
EP4323007A4 (de) Polypeptidformulierungen
IL311448A (en) Polypeptide
IL314723A (en) Novel peptides
IL311773A (en) Peptide
IL312470A (en) Novel proteins
EP3870698A4 (de) Antipathogene polypeptide
EP4165066A4 (de) Fusionspolypeptid
EP4204000A4 (de) Modifizierte polypeptide mit verbesserten eigenschaften
EP4441083A4 (de) Linc-komplex-hemmende polypeptide

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240806

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20260109

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/02 20060101AFI20260102BHEP

Ipc: A61K 39/00 20060101ALI20260102BHEP

Ipc: A61K 39/40 20060101ALI20260102BHEP

Ipc: A61P 31/04 20060101ALI20260102BHEP

Ipc: C07K 5/113 20060101ALI20260102BHEP

Ipc: C12N 9/52 20060101ALI20260102BHEP